Moreover, due to higher insulin/insulin-like growth factor signaling, men with prostate cancer harboring the TMPRSS2-ERG gene fusion are more susceptible to obesity and hence have poorer prognosis than those not harboring the gene fusion [175]. This evidence concerns the gene ERG and prostate carcinoma.